Opal Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Opal Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-72,251	Closed	-$173K	–	244
2025 Q4	$173K	Buy	+72,251	New	+$105K	0.04%	182

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Opal Capital's ZNTL Position: Q1 2026 in Review

Opal Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2026, closing a stake of 72,251 shares — an estimated $173K sold.

Opal Capital first reported a position in ZNTL in Q4 2025 and held it in 1 quarter. The position peaked at $173K in Q4 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Opal Capital reported no remaining Zentalis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Opal Capital sold 72,251 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $173K.
Opal Capital first reported a position in Zentalis Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Opal Capital's Zentalis Pharmaceuticals position peaked at $173K in Q4 2025.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Opal Capital's 13F filing for Q1 2026, filed 18 May 2026.